The ad works as Denmark fires all wood facing a record record of Covid-19 cases and a soaring of Omicron Variant, which should become dominant in Copenhagen this week.
Le Monde with AFP
Refused by France because considered insufficiently effective, Molnupiravir, COVID treatment of the US Merck laboratory, has been authorized in Denmark for patients at risk with symptoms, Thursday, December 16. The country has become first member of the European Union to authorize this treatment, marketed under the name of LageVrio.
“We recommend treatment by cache because we believe that the benefits outweigh the disadvantages for patients who have the greatest risk of becoming sick of CVIV-19,” announced a leader of the National Agency Danish Health (SST), Kirstine Moll Harboe, in a Communiqué . “We are fully aware that it is a new and unapproved treatment on which we do not yet have a lot of knowledge,” said SST that ensures the effects of treatment closely.
Outbreak in Denmark
The ad works as Denmark fires all wood facing a record record of Covid-19 cases and a soaring of the new Omicron variant, which should become dominant in Copenhagen this week.
The daily number of new cases was 8 770 on Wednesday, the highest figure ever reported for the 5.8 million inhabitants. “We hope that the treatment will help reduce the number of hospitalizations in patients at high risk of serious illness,” added Moll Harboe. In Denmark, 508 people are currently hospitalized, including 66 in intensive care.
Marketed in the form of stamps, this treatment was approved in mid-November by the European regulator for urgent use, before its formal marketing authorization. The LageVrio has been authorized since November in the United Kingdom and during the United States, but its less good results than hopefuls grow countries to wait.
The complete results of the clinical trial released on November 26 by MERck / MSD show a much lower efficiency than the one announced at Grand Noise in early October on the basis of intermediate database. According to these complete results, the drug reduces by 30% – and not half as initially announced – the hospitalization and death rate in patients at risk having taken shortly after the infection.
Norway signed a bilateral agreement on Wednesday with Merck to ensure fast shipments of treatment, but it still awaits the green light of the European Medicines Agency to approve it.